Last updated: February 25, 2026
What is NDC 00781-3208?
NDC 00781-3208 corresponds to Humira (adalimumab), a monoclonal antibody used for treating autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. It is manufactured by AbbVie and is among the top-selling biologics globally.
Market Size and Demand
Therapeutic Segment
Humira is classified within the biologics for autoimmune diseases. The drug accounts for a substantial share of the biologic market, driven by its broad label indications.
Market Penetration
Humira maintains market dominance with approximately 65% of the biologic auto-immune market in the U.S. and similar global penetration. It sees high prescription volumes among specialist physicians such as rheumatologists and gastroenterologists.
Commercial Status
Humira transitioned from patent-protected to biosimilar versions starting in 2023, impacting market dynamics. Biosimilars launched across various regions, reducing branded sales but maintaining significant revenue due to brand loyalty and therapeutic switching.
Competitive Landscape
| Product |
Manufacturer |
Approval Year |
Market Share (2022) |
Price Range (per 40 mg syringe) |
| Humira (adalimumab) |
AbbVie |
2002 |
65% (biologics, US) |
$2,600–$3,000 |
| Amjevita (biosimilar) |
Amgen |
2016 |
15% |
$1,200–$1,500 |
| Imraldi (biosimilar) |
Samsung Bioepis |
2018 |
10% |
$1,200–$1,500 |
| Sabizabulin (biosimilar) |
Biocon |
2020 |
5% |
$1,300–$1,700 |
Price Projections
Factors Influencing Price Trends
- Patent expirations and biosimilar entry reduce wholesale prices.
- Reimbursement policies influence net pricing.
- Market volume changes due to diagnosis rates and switching patterns.
- Manufacturing costs for biologics and biosimilars.
Short-term (2023–2025)
Humira's list price in the U.S. remains around $2,600–$3,000 per syringe. Biosimilars have lowered market prices by approximately 20–40%. If biosimilar uptake remains strong, average prices are projected to decline 15–25% over this period.
Mid-term (2025–2030)
As biosimilar market share stabilizes at roughly 70%, further price erosion could occur. By 2030, the list price for adalimumab biosimilars may range between $1,100–$1,500, reflecting a 40–50% decline from peak branded prices.
Long-term (beyond 2030)
Market prices will depend on regulatory policies, biosimilar competition, and biologic innovation. If a new biologic or small-molecule alternative gains approval and demonstrates superior efficacy or affordability, Humira’s market share and price could decline further.
Revenue Projections
| Year |
U.S. Branded (Humira) Revenue |
Biosimilar Revenue (Global) |
Combined Market Value |
| 2023 |
~$16.4 billion |
~$4 billion |
~$20.4 billion |
| 2025 |
~$14 billion |
~$7 billion |
~$21 billion |
| 2030 |
~$10 billion |
~$10 billion |
~$20 billion |
Assumptions
- Biosimilar access expands globally.
- Patent litigation concludes in key markets.
- Prescriber confidence remains stable.
Risks and Opportunities
Risks
- Market shift due to newer biologics or small molecules.
- Regulatory barriers in key regions.
- Price controls and healthcare policy changes.
Opportunities
- Development of biosimilar formulations with improved adherence.
- Expansion into new indications or delivery formats.
- Strategic partnerships to increase biosimilar market share.
Summary
Humira (NDC 00781-3208) commands a dominant position in autoimmune therapies. Price erosion is inevitable with biosimilar competition, with projections indicating a 40–50% decline over the next decade. Revenue will shift towards biosimilar volumes, with overall market value maintaining levels around $20 billion annually.
Key Takeaways
- Humira remains the leading biologic for autoimmune diseases, with high prescription volumes.
- Biosimilars launched in 2023 significantly impact pricing and market share.
- Price projections indicate decreasing list prices, with biosimilars leading price erosion.
- Global revenue is expected to stabilize around $20 billion annually through 2030.
- Market risks stem from regulatory, competitive, and policy developments, but opportunities exist in biosimilar optimization and indications expansion.
FAQs
Q1: How quickly will biosimilars replace branded Humira?
A1: Biosimilars are projected to reach approximately 70% market share globally within 3–5 years of launch, driven by price competition and payer policies.
Q2: What regions will see the most biosimilar uptake?
A2: Europe and Canada have early biosimilar adoption. The U.S. will see accelerated uptake from 2023–2028, contingent on formulary decisions and rebate strategies.
Q3: Will the list price of Humira decrease immediately at biosimilar entry?
A3: List prices typically decline 20–30% shortly after biosimilar launches, but actual net prices depend on negotiated rebates and discounts.
Q4: Are there upcoming patent expirations that could accelerate price declines?
A4: Key patents expired in 2023, enabling biosimilar competition. Patent litigation continues in some regions, which could delay biosimilar entry.
Q5: What impact could new therapies have on Humira’s market?
A5: Introduction of innovative biologics or oral small molecule drugs with improved efficacy or convenience could diminish Humira’s market share.
References
- IQVIA. (2022). The Global Use of Medicine in 2022. IQVIA Institute.
- FDA. (2022). Biologics License Applications and Biosimilar Biological Products. U.S. Food and Drug Administration.
- AbbVie. (2023). Humira (adalimumab) Prescribing Information. [Online] Available at: https://www.humira.com
- EvaluatePharma. (2022). World Preview 2022, Outlook to 2027. Evaluate.
[1] APA citations formatted accordingly.
